Page 1645 - Williams Hematology ( PDFDrive )

1620 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1621

79. Schmitz R, Hansmann ML, Bohle V, et al: TNFAIP3 (A20) is a tumor suppressor gene 108. Allemani C, Sant M, De Angelis R, et al: Hodgkin disease survival in Europe and the
in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206: U.S.: Prognostic significance of morphologic groups. Cancer 107:352–360, 2006.
981–989, 2009. 109. Diehl V, Sextro M, Franklin J, et al: Clinical presentation, course, and prognostic factors
80. Baus D, Pfitzner E: Specific function of STAT3, SOCS1, and SOCS3 in the regulation in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodg-
of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 118: kin’s disease: Report from the European Task Force on Lymphoma Project on Lympho-
1404–1413, 2006. cyte-Predominant Hodgkin’s Disease. J Clin Oncol 17:776–783, 1999.
81. Kapp U, Yeh WC, Patterson B, et al: Interleukin 13 is secreted by and stimu- 110. Kaplan HS. Hodgkin’s Disease, ed 2. Harvard University Press, Cambridge, MA, 1980.
lates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189:1939–1946, 111. Rosenberg SA, Kaplan HS: Evidence for an orderly progression in the spread of Hodg-
1999. kin’s disease. Cancer Res 26:1225–1231, 1966.
82. Lamprecht B, Kreher S, Anagnostopoulos I, et al: Aberrant expression of the Th2 cytok- 112. Smithers DW: Spread of Hodgkin’s disease. Lancet 1:1262–1267, 1970.
ine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells 113. Rappaport H, Berard CW, Butler JJ, et al: Report of the Committee on Histopatholog-
via regulation of MIP-3alpha. Blood 112:3339–3347, 2008. ical Criteria Contributing to Staging of Hodgkin’s Disease. Cancer Res 31:1864–1865,
83. Chiu A, Xu W, He B, et al: Hodgkin lymphoma cells express TACI and BCMA receptors 1971.
and generate survival and proliferation signals in response to BAFF and APRIL. Blood 114. Kirschner RH, Abt AB, O’Connell MJ, et al: Vascular invasion and hematogenous dis-
109:729–739, 2007. semination of Hodgkin’s disease. Cancer 34:1159–1162, 1974.
84. Fiumara P, Snell V, Li Y, et al: Functional expression of receptor activator of nuclear 115. Haybittle JL, Hayhoe FG, Easterling MJ, et al: Review of British National Lymphoma
factor kappaB in Hodgkin disease cell lines. Blood 98:2784–2790, 2001. Investigation studies of Hodgkin’s disease and development of prognostic index. Lancet
85. Ebstein WV: Das chronische Ruckfallsfieber, eine neu infectionskrankheit. Berl Klin 1:967–972, 1985.
Wochenschr 24:565, 1887. 116. Le Bourgeois JP, Tubiana M: The erythrocyte sedimentation rate as a monitor for
86. Pel PK: Zur symptomatolgie der sogennanten pseudoleukamie. II. Pseudokeukamie relapse in patients with previously treated Hodgkin’s disease. Int J Radiat Oncol Biol
oder chronisches Ruckfallsfieber? Berl Klin Wochenschr 24:844, 1887. Phys 2:241–247, 1977.
87. Atkinson K, Austin DE, McElwain TJ, et al: Alcohol pain in Hodgkin’s disease. Cancer 117. Tubiana M, Henry-Amar M, van der Werf-Messing B, et al: A multivariate analysis
37:895–899, 1976. of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:
88. Rueffer U, Sieber M, Josting A, et al: Prognostic factors for subdiaphragmatic involve- 23–30, 1985.
ment in clinical stage I-II supradiaphragmatic Hodgkin’s disease: A retrospective anal- 118. Friedenberg WR, Gatlin PF, Mazza JJ, et al: Prognostic value of serum lactic dehydroge-
ysis of the GHSG. Ann Oncol 10:1343–1348, 1999. nase level in Hodgkin’s disease. J Lab Clin Med 103:489–490, 1984.
89. Audard V, Larousserie F, Grimbert P, et al: Minimal change nephrotic syndrome and 119. Schilling RF, McKnight B, Crowley JJ: Prognostic value of serum lactic dehydrogenase
classical Hodgkin’s lymphoma: Report of 21 cases and review of the literature. Kidney level in Hodgkin’s disease. J Lab Clin Med 99:382–387, 1982.
Int 69:2251–2260, 2006. 120. Mercier RJ, Thompson JM, Harman GS, et al: Recurrent hypercalcemia and ele-
90. Barta SK, Yahalom J, Shia J, et al: Idiopathic cholestasis as a paraneoplastic phenome- vated 1,25-dihydroxyvitamin D levels in Hodgkin’s disease. Am J Med 84:165–168,
non in Hodgkin’s lymphoma. Clin Lymphoma Myeloma 7:77–82, 2006. 1988.
91. Cavalli F: Rare syndromes in Hodgkin’s disease. Ann Oncol 9 Suppl 5:S109–S113, 1998. 121. Braund WJ, Naylor BA, Williamson DH, et al: Autoimmunity to insulin receptor and
92. Gerstner ER, Abrey LE, Schiff D, et al: CNS Hodgkin lymphoma. Blood 112:1658–1661, hypoglycaemia in patient with Hodgkin’s disease. Lancet 1:237–240, 1987.
2008. 122. Walters EG, Tavare JM, Denton RM, et al: Hypoglycaemia due to an insulin-receptor
93. Filly R, Bland N, Castellino RA: Radiographic distribution of intrathoracic disease in antibody in Hodgkin’s disease. Lancet 1:241–243, 1987.
previously untreated patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. 123. Eliakim R, Vertman E, Shinhar E: Syndrome of inappropriate secretion of antidiuretic
Radiology 120:277–281, 1976. hormone in Hodgkin’s disease. Am J Med Sci 291:126–127, 1986.
94. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, 124. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. Inter-
staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lug- national Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med
ano classification. J Clin Oncol 32:3059–3068, 2014. 339:1506–1514, 1998.
95. Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and 125. Dimopoulos MA, Cabanillas F, Lee JJ, et al: Prognostic role of serum beta 2-microglobulin
response assessment of lymphoma: Consensus of the International Conference on in Hodgkin’s disease. J Clin Oncol 11:1108–1111, 1993.
Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048–3058, 2014. 126. Kurzrock R, Redman J, Cabanillas F, et al: Serum interleukin 6 levels are elevated in
96. Kostakoglu L, Cheson BD: Current role of FDG PET/CT in lymphoma. Eur J Nucl Med lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with
Mol Imaging 41:1004–1027, 2014. B symptoms. Cancer Res 53:2118–2122, 1993.
97. Dann EJ, Bar-Shalom R, Tamir A, et al: Risk-adapted BEACOPP regimen can reduce 127. Nadali G, Vinante F, Ambrosetti A, et al: Serum levels of soluble CD30 are elevated in
the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma the majority of untreated patients with Hodgkin’s disease and correlate with clinical
with no impairment of outcome. Blood 109:905–909, 2007. features and prognosis. J Clin Oncol 12:793–797, 1994.
98. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-d-glucose 128. Pizzolo G, Chilosi M, Vinante F, et al: Soluble interleukin-2 receptors in the serum of
positron emission tomography is prognostically superior to international prognostic patients with Hodgkin’s disease. Br J Cancer 55:427–428, 1987.
score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish 129. Sarris AH, Kliche KO, Pethambaram P, et al: Interleukin-10 levels are often elevated
study. J Clin Oncol 25:3746–3752, 2007. in serum of adults with Hodgkin’s disease and are associated with inferior failure-free
99. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy survival. Ann Oncol 10:433–440, 1999.
predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 130. Lieberman DA: Intrahepatic cholestasis due to Hodgkin’s disease. An elusive diagnosis.
107:52–59, 2006. J Clin Gastroenterol 8:304–307, 1986.
100. Press OW, LeBlanc M, Rimsza LM, et al: A phase II trial of response-adapted therapy 131. Routledge RC, Hann IM, Jones PH: Hodgkin’s disease complicated by the nephrotic
of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Inter- syndrome. Cancer 38:1735–1740, 1976.
group S0816. Hematol Oncol 31 (Suppl1):137, 2013. 132. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell
101. Raemaekers JM, Andre MP, Federico M, et al: Omitting radiotherapy in early posi- lymphoma differs from that of other diffuse large B-cell lymphomas and shares features
tron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an with classical Hodgkin lymphoma. Blood 102:3871–3879, 2003.
increased risk of early relapse: Clinical results of the preplanned interim analysis of the 133. Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary mediastinal
randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194, 2014. B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lym-
102. Radford J, Barrington S, Counsell N, et al: Involved field radiotherapy versus no further phoma related to Hodgkin lymphoma. J Exp Med 198:851–862, 2003.
treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a “negative” 134. Kondratiev S, Duraisamy S, Unitt CL, et al: Aberrant expression of the dendritic cell
PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID trial. Blood 120 (ASH marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediasti-
Annual Meeting Abstracts): 547, 2012. nal large B-cell lymphoma distinguishes these tumor types from morphologically and
103. Nogova L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodg- phenotypically similar lymphomas. Am J Surg Pathol 35:1531–1539, 2011.
kin’s lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J 135. Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 ampli-
Clin Oncol 26:434–439, 2008. fication, increased PD-1 ligand expression, and further induction via JAK2 in nodular
104. Advani RH, Hoppe RT: How I treat nodular lymphocyte predominant Hodgkin lym- sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood
phoma. Blood 122:4182–4188, 2013. 116:3268–3277, 2010.
105. Miettinen M, Franssila KO, Saxen E: Hodgkin’s disease, lymphocytic predominance 136. Brassesco MS: Leukemia/lymphoma-associated gene fusions in normal individuals.
nodular. Increased risk for subsequent non-Hodgkin’s lymphomas. Cancer 51:2293– Genet Mol Res 7:782–790, 2008.
2300, 1983. 137. Kaplan HS, Rosenberg SA: The treatment of Hodgkin’s disease. Med Clin North Am
106. Sundeen JT, Cossman J, Jaffe ES: Lymphocyte predominant Hodgkin’s disease nodular 50:1591–1610, 1966.
subtype with coexistent “large cell lymphoma.” Histological progression or composite 138. Feuer EJ, Kessler LG, Baker SG, et al: The impact of breakthrough clinical trials on
malignancy? Am J Surg Pathol 12:599–606, 1988. survival in population based tumor registries. J Clin Epidemiol 44:141–153, 1991.
107. Rudiger T, Gascoyne RD, Jaffe ES, et al: Workshop on the relationship between nodular 139. Santoro A, Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodg-
lymphocyte predominant Hodgkin’s lymphoma and T cell/histiocyte-rich B cell lym- kin’s disease after treatment with Adriamycin, bleomycin, vinblastine and dacarbazine
phoma. Ann Oncol 13 Suppl 1:44–51, 2002. (ABVD). Cancer Chemother Pharmacol 2:101–105, 1979.

Kaushansky_chapter 97_p1603-1624.indd 1620 9/18/15 11:12 PM